Jeil Pharmaceutical Co.,Ltd

KSE 271980.KS

Jeil Pharmaceutical Co.,Ltd EBITDA Margin for the year ending December 31, 2023: 2.44%

Jeil Pharmaceutical Co.,Ltd EBITDA Margin is 2.44% for the year ending December 31, 2023, a 1,557.07% change year over year. EBITDA Ratio is the proportion of Earnings Before Interest, Taxes, Depreciation, and Amortization to total revenue, assessing a company's operational profitability before non-operating expenses and non-cash charges.

Jeil Pharmaceutical Co.,Ltd EBITDA Margin for the year ending December 31, 2022 was -0.17%, a 41.92% change year over year.
Jeil Pharmaceutical Co.,Ltd EBITDA Margin for the year ending December 31, 2021 was -0.29%, a -108.82% change year over year.
Jeil Pharmaceutical Co.,Ltd EBITDA Margin for the year ending December 31, 2020 was 3.27%, a 158.13% change year over year.
Jeil Pharmaceutical Co.,Ltd EBITDA Margin for the year ending December 31, 2019 was 1.27%, a -39.44% change year over year.

Key data

Date	EBITDA Margin	EBIT Margin	Depreciation and Amortization	EBIT

KSE: 271980.KS

Jeil Pharmaceutical Co.,Ltd

CEO	Seok-Jae Sung
IPO Date	July 18, 2017
Location	South Korea
Headquarters	343, Sapyeong-daero
Employees	973
Sector	Consumers Staples
Industries Personal Care Baby & Childcare Cleaning Supplies Cosmetics Hardware & Electronics Non-Alcoholic Beverages Pharmaceuticals Plastics

Description

Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company also exports its products to approximately 40 countries in ASEAN, Central and South America, Africa, and internationally. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, South Korea.

Key trends

Past 5 years